The fasting serum concentrations of total homocysteine and metabolites of transsulfuration (cystathionine, cysteine, methylmalonic acid, 2-methylcitric acid) and remethylation (methionine) were determined by gas chromatography-mass spectrometry in 40 nondialyzed patients with chronic renal disease and in 50 patients with end-stage renal disease requiring chronic maintenance hemodialysis. The nondialyzed patients and 28 of the dialysis patients did not receive additional vitamin supplementations. Twenty-two of the dialysis patients received daily oral vitamin preparations containing 10 mg pyridoxine (vitamin B6), 6 µg cyanocobalamin (vitamin B12), and 1 mg folic acid. In the nondialyzed patients, linear regression analysis showed positive correlations between serum concentrations of creatinine and total homocysteine (r = 0.68, p < 0.0001), cystathionine (r = 0.73, p < 0.0001), methylmalonic acid (r = 0.77, p < 0.0001), and 2-methylcitric acid (r = 0.81, p < 0.0001). Serum homocysteine was positively correlated with serum concentrations of cystathionine (r = 0.59, p < 0.0001), cysteine (r = 0.69, p = 0.004), methylmalonic acid (r = 0.64, p = 0.0001), and 2-methylcitric acid (r = 0.64, p < 0.0001). There was no significant correlation between serum concentrations of homocysteine and methionine (r = –0.14, p = 0.63). In the hemodialysis patients receiving oral vitamin supplementation, serum homocysteine and cystathionine concentrations were significantly lower than in hemodialysis patients not receiving vitamins (homocysteine 21.8 ± 1.1 vs. 33.2 ± 3.7 µmol/l, p = 0.0004; cystathionine 2,075.9 ± 387.1 vs. 3,171.3 ± 680.2 nmol/l, p = 0.02; mean ± SEM). In summary, our results show increased intermediate products of the transsulfuration pathway, but no increase in remethylation of homocysteine in chronic renal disease, including end-stage renal disease requiring chronic maintenance dialysis.

Keywords:
Chronic renal failure, Homocysteine metabolism, Alterations, homocysteine levels
1.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049–1057.
2.
Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–881.
3.
Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PWF, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH: Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286–291.
4.
Arnesen E, Refsum H, Býnaa KH, Ueland PM, Fýrde OH, Nordrehaug JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704–709.
5.
Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395–1398.
6.
Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH: Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764–1779.
7.
Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131–138.
8.
Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Diseases. New York, McGraw-Hill, 1989, vol 1, pp 693–734.
9.
Rosenberg IH, Fenton WA: Disorders of propionate and methylmalonate metabolism; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Diseases. New York, McGraw-Hill, 1989, vol 1, pp 821–844.
10.
Stabler SP, Marcell PD, Podell ER, Allen RH, Lindenbaum J: Assay of methylmalonic acid in the serum of patients with cobalamin deficiency using capillary gas chromatography-mass spectrometry. J Clin Invest 1986;77:1606–1612.
11.
Allen RH, Stabler SP, Savage DG, Lindenbaum J: Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism 1993;42:978–988.
12.
Kang SS, Passen EL, Ruggie N, Wong PW, Sora H: Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993;88:1463–1469.
13.
Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536–545.
14.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.
15.
Goyette P, Frosst P, Rosenblatt DS, Rozen R: Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995;56:1052–1059.
16.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149–1155.
17.
Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10–20.
18.
Cohen BD, Patel H, Kornhauser RS: Alternate reasons for atherogenesis in uremia. Proc Clin Dial Transplant Forum 1977;7:178–180.
19.
Wilcken DEL, Gupta VJ: Sulphur-containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301–307.
20.
Wilcken DEL, Gupta VJ, Betts AK: Homocysteine in the plasma of renal transplant recipients: Effect of cofactors for methionine metabolism. Clin Sci 1981;61:743–749.
21.
Smolin LA, Laidlaw SA, Kopple JD: Altered plasma-free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987;45:737–743.
22.
Chauveau P, Chadefaux B, Coude M, et al: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43(suppl 41):72–77.
23.
Stabler SP, Lindenbaum J, Savage DG, Allen RH: Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404–3413.
24.
Kim SS, Hirose S, Tamura H, Nagasawa R, Tokushima H, Mitarai T, Isoda K: Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 1994;10:282–285.
25.
Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drüeke TB, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteineamia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994;9:1103–1108.
26.
Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H: Hyperhomocysteinemia in cyclosporin-treated renal transplant recipients. Transplantation 1996;61:509–512.
27.
Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PW, et al: Hyperhomocysteinemia and traditional cardiovascular disease riks factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 1995;114:93–103.
28.
Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121–125.
29.
Shemin D, Lapane KL, Bausserman L, Kanaan E, Dworkin L, Bostom AG: Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 1999;10:1095–1099.
30.
Perna AF, Ingrosso D, Castaldo P, De Santo NG, Galletti P, Zappia V: Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner Electrolyte Metab 1999;25:95–99.
31.
Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A: Hyperhomocysteinaemia in stroke: Prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214–221.
32.
Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
33.
Stabler SP, Marcell PD, Podell ER, Allen RH: Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 1987;162:185–196.
34.
Allen RH, Stabler SP, Lindenbaum J: Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 1993;42:1448–1460.
35.
Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH: Metabolic evidence that deficiencies of vitamin B12 (cobalamin), folate, and vitamin B6 occur commonly in elderly people. Am J Clin Nutr 1993;58:468–476.
36.
Norusis MJ (ed): Advanced Statistics. Chicago, SPSS, 1988.
37.
Ueland PM, Refsum H: Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473–501.
38.
House JD, Brosnan ME, Brosnan JT: Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. Kidney Int 1998;54:1601–1607.
39.
Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230–234.
40.
Foreman JW, Wlad H, Blumberg G, Pepe LM, Segal S: Homocystine uptake in isolated rat renal cortical tubules. Metabolism 1982;31:613–619.
41.
van Guldener C, Donker AJM, Jakobs C, Teerlink T, de Meer K, Stehouwer CDA: No net renal extraction of homocysteine in fasting humans. Kidney Int 1998;54:166–169.
42.
Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia F: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995;47:247–253.
43.
Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495–502.
44.
Dudman NPB, Tyrrell PA, Wilcken DEL: Homocysteinemia: Depressed plasma serine levels. Metabolism 1987;36:198–202.
45.
Arnadottir M, Brattström L, Simonsen O, Thyssell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993;40:236–240.
46.
Savage DG, Lindenbaum J, Stabler SP, Allen RH: Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994;96:239–246.
47.
Bocock MA, Zlotkin SH: Hepatic sulfur amino acid metabolism in rats with chronic renal failure. J Nutr 1990;120:691–699.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.